99 related articles for article (PubMed ID: 7748192)
1. 5-Fluoro-2-pyrimidinone, a liver aldehyde oxidase-activated prodrug of 5-fluorouracil.
Guo X; Lerner-Tung M; Chen HX; Chang CN; Zhu JL; Chang CP; Pizzorno G; Lin TS; Cheng YC
Biochem Pharmacol; 1995 Apr; 49(8):1111-6. PubMed ID: 7748192
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of fluorouracil and folinic acid.
Schalhorn A; Kühl M
Semin Oncol; 1992 Apr; 19(2 Suppl 3):82-92. PubMed ID: 1557660
[TBL] [Abstract][Full Text] [Related]
3. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
Fukushima M; Iizuka K; Jin C; Zhang C; Hong M; Eshima K
Drug Des Devel Ther; 2017; 11():1693-1705. PubMed ID: 28652707
[TBL] [Abstract][Full Text] [Related]
4. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.
Baccanari DP; Davis ST; Knick VC; Spector T
Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11064-8. PubMed ID: 8248211
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Hidalgo M; Villalona-Calero MA; Eckhardt SG; Drengler RL; Rodriguez G; Hammond LA; Diab SG; Weiss G; Garner AM; Campbell E; Davidson K; Louie A; O'Neil JD; von Borstel R; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2000 Jan; 18(1):167-77. PubMed ID: 10623707
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
7. A 5-FU Precursor Designed to Evade Anabolic and Catabolic Drug Pathways and Activated by Pd Chemistry
Adam C; Bray TL; Pérez-López AM; Tan EH; Rubio-Ruiz B; Baillache DJ; Houston DR; Salji MJ; Leung HY; Unciti-Broceta A
J Med Chem; 2022 Jan; 65(1):552-561. PubMed ID: 34979089
[TBL] [Abstract][Full Text] [Related]
8. Covalently mucoadhesive amphiphilic prodrug of 5-fluorouracil for enhanced permeation and improved oral absorption.
Liu Y; Zhao D; Sun M; Wei W; Wang Y; Zhou J; Zhang R; Wang J; Zhang H; He Z; Kan Q; Sun J
Drug Deliv Transl Res; 2018 Jun; 8(3):645-656. PubMed ID: 29532356
[TBL] [Abstract][Full Text] [Related]
9. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Okuda H; Ogura K; Kato A; Takubo H; Watabe T
J Pharmacol Exp Ther; 1998 Nov; 287(2):791-9. PubMed ID: 9808711
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of intravitreal 5-fluorouracil prodrugs in silicone oil: experimental studies in pigs.
Schmidt Laugesen C; Steffansen B; Scherfig E; la Cour M
Acta Ophthalmol Scand; 2005 Apr; 83(2):184-90. PubMed ID: 15799730
[TBL] [Abstract][Full Text] [Related]
11. In vivo evaluation of a novel antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation.
Shibamoto Y; Zhou L; Hatta H; Mori M; Nishimoto SI
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):407-13. PubMed ID: 11173134
[TBL] [Abstract][Full Text] [Related]
12. A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity.
Zhao D; Zhang H; Tao W; Wei W; Sun J; He Z
Biomater Sci; 2017 Feb; 5(3):502-510. PubMed ID: 28116362
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.
Miller CR; Williams CR; Buchsbaum DJ; Gillespie GY
Cancer Res; 2002 Feb; 62(3):773-80. PubMed ID: 11830532
[TBL] [Abstract][Full Text] [Related]
14. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase.
Huber BE; Austin EA; Good SS; Knick VC; Tibbels S; Richards CA
Cancer Res; 1993 Oct; 53(19):4619-26. PubMed ID: 8402637
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment.
Anitha A; Deepa N; Chennazhi KP; Lakshmanan VK; Jayakumar R
Biochim Biophys Acta; 2014 Sep; 1840(9):2730-43. PubMed ID: 24946270
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine.
Wallace PM; MacMaster JF; Smith VF; Kerr DE; Senter PD; Cosand WL
Cancer Res; 1994 May; 54(10):2719-23. PubMed ID: 8168103
[TBL] [Abstract][Full Text] [Related]
17. 5-ethynyl-2(1H)-pyrimidinone: aldehyde oxidase-activation to 5-ethynyluracil, a mechanism-based inactivator of dihydropyrimidine dehydrogenase.
Porter DJ; Harrington JA; Almond MR; Lowen GT; Zimmerman TP; Spector T
Biochem Pharmacol; 1994 Mar; 47(7):1165-71. PubMed ID: 8161345
[TBL] [Abstract][Full Text] [Related]
18. Mechanism for resistance to 5-fluorouracil in P388 leukemia cells.
Mitsuhashi J; Inaba M
J Pharmacobiodyn; 1991 Oct; 14(10):577-81. PubMed ID: 1818099
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Baker SD; Khor SP; Adjei AA; Doucette M; Spector T; Donehower RC; Grochow LB; Sartorius SE; Noe DA; Hohneker JA; Rowinsky EK
J Clin Oncol; 1996 Dec; 14(12):3085-96. PubMed ID: 8955653
[TBL] [Abstract][Full Text] [Related]
20. Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: preparation and in vivo evaluation.
Pangeni R; Choi SW; Jeon OC; Byun Y; Park JW
Int J Nanomedicine; 2016; 11():6379-6399. PubMed ID: 27942212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
